EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial

Anna-Maria Hoffmann-Vold, Shervin Assassi, Vincent Cottin, Michael Kreuter, Claudia Valenzuela, Marlies S Wijsenbeek, Hui Gu, Madhu Kanakapura, Ivana Ritter, Susanne Stowasser, Gerrit Weimann, Toby M Maher

Annals of the Rheumatic Diseases · 2026-10 · 85 (10) · 2004-2013

DOI: 10.1016/j.ard.2026.03.027 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-10. Verfasst von Anna-Maria Hoffmann-Vold und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Oslo University Hospital, Oslo, Norway; Department of Rheumatology, University Hospital Zurich, University of Zurich, Zur…. Hauptthemen laut MEDLINE: Autoimmune Diseases, Pulmonary Fibrosis, Lung Diseases, Interstitial. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aimed to investigate the effects of nerandomilast in patients with autoimmune disease-related interstitial lung diseases (autoimmune ILDs) and progressive pulmonary fibrosis (PPF) in the FIBRONEER-ILD trial. METHODS: Patients with PPF were randomised to receive nerandomilast 9 mg twice a day, nerandomilast 18 mg twice a day, or placebo. Among patients with autoimmune ILDs, we evaluated the change in forced vital capacity (FVC) at week 52, and time-to-event endpoints and adverse events over the whole trial. RESULTS: Among 325 patients with autoimmune ILDs, adjusted mean (SE) changes in FVC (mL) at week 52 were -107.1 (25.0) in the placebo group, -61.2 (23.3) in the nerandomilast 9 mg twice a day group (difference vs placebo: 45.9 [95% CI: -20.8 to 112.6]), and -64.9 (23.5) in the nerandomilast 18 mg twice a day group (difference vs placebo: 42.2 [-24.9, 109.3]). Over the whole trial (mean exposure to trial medication: 15.8 months), the hazard ratio (HR) vs placebo for time to first acute exacerbation of ILD, hospitalisation for respiratory cause, or death was 0.66 (95% CI: 0.40-1.10) for nerandomilast 9 mg twice a day and 0.56 (0.33-0.94) for nerandomilast 18 mg twice a day, and the HR for time to death was 0.40 (0.17-0.94) for nerandomilast 9 mg twice a day and 0.28 (0.11-0.69) for nerandomilast 18 mg twice a day. Adverse events led to treatment discontinuation in 13.0%, 8.0%, and 10.6% of the placebo, nerandomilast 9 mg twice a day, and nerandomilast 18 mg twice a day groups, respectively. CONCLUSIONS: Consistent with the overall trial population, among patients with autoimmune ILDs in FIBRONEER-ILD, nerandomilast slowed progression of pulmonary fibrosis and was well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesPulmonary FibrosisLung Diseases, InterstitialHumansFemaleMaleMiddle AgedTreatment OutcomeDisease ProgressionVital CapacityDouble-Blind MethodAgedCyclobutanesPiperidines

Substanzen

nerandomilastCyclobutanesPiperidines

Autor:innen und Institutionen

  • Department of Rheumatology, Oslo University Hospital, Oslo, Norway; Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Electronic address: a.m.hoffmann-vold@medisin.uio.no.
  • Division of Rheumatology, UTHealth Houston, Houston, Texas, USA.
  • National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR 754, ERN-LUNG, Lyon, France.
  • Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center and Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany.
  • Pulmonology Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain.
  • Center of Expertise for Interstitial Lung Diseases, Department of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands.

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Hoffmann-Vold, A. M., Assassi, S., Cottin, V., Kreuter, M., Valenzuela, C., Wijsenbeek, M. S., Gu, H., Kanakapura, M., Ritter, I., Stowasser, S., Weimann, G., & Maher, T. M. (2026). Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial. Annals of the Rheumatic Diseases, 85(10), 2004-2013. https://doi.org/10.1016/j.ard.2026.03.027

Vancouver

Hoffmann-Vold AM, Assassi S, Cottin V, Kreuter M, Valenzuela C, Wijsenbeek MS, et al. Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial. Annals of the Rheumatic Diseases. 2026;85(10):2004-2013. doi:10.1016/j.ard.2026.03.027

BibTeX
@article{HoffmannVold2026,
  author = {Hoffmann-Vold, Anna-Maria and Assassi, Shervin and Cottin, Vincent and Kreuter, Michael and Valenzuela, Claudia and Wijsenbeek, Marlies S and Gu, Hui and Kanakapura, Madhu and Ritter, Ivana and Stowasser, Susanne and Weimann, Gerrit and Maher, Toby M},
  title = {Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  volume = {85},
  number = {10},
  pages = {2004--2013},
  doi = {10.1016/j.ard.2026.03.027}
}
Kostenlos starten →